RE-BVS – Piemonte Repository

Sfoglia per AUTORE
SANCETTA R
Collezione AOU Alessandria

Items : 5

The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan. in Clinical lymphoma, myeloma & leukemia / Clin Lymphoma Myeloma Leuk. 2024 May;24(5):323-331. doi: 10.1016/j.clml.2024.01.008. Epub 2024 Jan 2

2024
AOU Alessandria
AOU San Luigi di Orbassano
AOU Novara

Roccaro AM; Pellizzeri S; Butturini G; Bernardi S; Farina M; Defina M; Russo Rossi A; Russo S; Romano A; Tiribelli M; De Gobbi M; Coppi MR; Corsetti MT; Sancetta R; Rosti G; Lemoli RM; Castagnetti F; Lunghi F; Crugnola M; Ferrari ML; D'Adda M; Lunghi M; Stagno F; Binotto G; Abruzzese E; Bonifacio M; Russo D; Bucelli C; Iurlo A; et alii...

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts. in American journal of hematology / Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24.

2023
AOU Alessandria
ASL Città di Torino
ASL Torino 4
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Della Porta MG; Santini V; Naldi I; Finelli C; Sancetta R; Selleri C; Pasini P; Giordano L; Turrini M; Tosi P; Tanasi I; Frigeni M; Grimaldi D; Marchetti M; Norata M; Galimberti S; Fianchi L; Di Veroli A; Ferrara F; Di Bona E; Bono R; Castelli A; Calvisi A; Rivoli G; Molteni A; Nicolino B; Occhini U; Leuzzi L; Genua A; et alii...

Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL. in Blood / Blood. 2022 Dec 1;140(22):2348-2357. doi: 10.1182/blood.2022016901.

2022
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Ghia P; Colia M; Ranghetti P; Perotta E; Capasso A; Varettoni M; Laurenti L; Coscia M; Rivela P; Sancetta R; Motta M; Reda G; Ferrario A; Moia R; Deodato M; Farina L; Schiattone L; Albi E; Scarano E; Heltai S; Scarfò L;

Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study. in Cancer medicine / Cancer Med. 2021 Mar;10(5):1726-1737. doi: 10.1002/cam4.3778. Epub 2021 Feb 16.

2021
AOU Alessandria
AOU San Luigi di Orbassano
AOU Novara

De Vivo A; Baccarani M; Roccaro AM; Polverelli N; Bernardi S; Farina M; Bocchia M; Gandolfi L; Aprile L; Russo S; Russo Rossi A; Tiribelli M; Romano A; Rege Cambrin G; Coppi MR; Corsetti MT; Sancetta R; Lemoli RM; Rosti G; Castagnetti F; Lunghi F; Ferrari ML; Crugnola M; Lunghi M; Binotto G; D'Adda M; Stagno F; Abruzzese E; Bonifacio M; et alii...

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. in Blood advances / Blood Adv. 2019 Dec 23;3(24):4280-4290. doi: 10.1182/bloodadvances.2019000865.

2019
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Soverini S; Vigneri P; Rosti G; Russo D; Saglio G; Castagnetti F; Pane F; Breccia M; Bonifacio M; Tomassetti S; Trabacchi E; Spadano R; Tiribelli M; Stagno F; Sancetta R; Sica S; Rege-Cambrin G; Rupoli S; Salvucci M; Rapezzi D; Pregno P; Palmieri F; Musolino C; Miggiano MC; Montefusco E; Melpignano A; Martino B; Marasca R; Lunghi M; et alii...